Panlong Pharmaceutical announced that in September 2023, the company issued 9.3527 million shares to specific targets at an issue price of 32.29 yuan per share, raising a total of 302 million yuan, with a net amount of 295 million yuan. The company previously signed a "Three-party Supervision Agreement on Raised Funds" with the sponsoring institution and related banks. As of the announcement date, the account at the Xi'an Software Park branch of Bank of China for the "Traditional Chinese Medicine Formula Granule R&D and Industrialization Project" has no balance and will be canceled in 2026, with the corresponding supervision agreement terminating simultaneously